ReviewNPJ vaccines2023
Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need.
Review in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Capsid inclusion in a CHIKV mRNA vaccine impairs adaptive immune responses.Cell reports. Medicine · 2026Article
- Chikungunya Vaccines in Travel Medicine: From Regulatory Approval to Real-World Challenges.Tropical medicine and infectious disease · 2026Review
- AGPAT1 is a novel Chikungunya virus receptor on human cells.Journal of virology · 2026Article
- The impact of variations in the chikungunya genome on the clinical manifestations and transmission of the disease.Journal of family medicine and primary care · 2025Review
- A Review of the Biology of Chikungunya Virus Highlighting the Development of Current Novel Therapeutic and Prevention Approaches.Pathogens (Basel, Switzerland) · 2025Review
- Re-emergence of chikungunya virus in China by 2025: What we know and what to do?PLoS pathogens · 2025Review
- Review
- De-risking vaccine development: lessons, challenges, and prospects.NPJ vaccines · 2025Review
- Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis.Reproductive health · 2025Article
- Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model.Viruses · 2025Article
- CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection.Signal transduction and targeted therapy · 2025Article
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection.Virulence · 2024Article
- Withaferin A inhibits Chikungunya virus nsP2 protease and shows antiviral activity in the cell culture and mouse model of virus infection.PLoS pathogens · 2024Article
- Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.Journal of travel medicine · 2024Review
- Article
- Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis.Vaccines · 2024Review
- Advancements in chikungunya virus management: FDA approval of ixchiq vaccine and global perspectives.Health science reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya is an arboviral disease caused by the chikungunya virus (CHIKV) afflicting tropical and sub-tropical countries worldwide. It has been identified as a priority pathogen by the Coalition for Epidemics Preparedness Innovations (CEPI) and as an emerging infectious disease (EID) necessitating further action as soon as possible by the World Health Organization (WHO). Recent studies suggest that disability-adjusted life years (DALYs) due to CHIKV infection are as high as 106,089 DALYs lost globally. Significant progress has been made in the development of several vaccines, aimed at preventing CHIKV infections. This perspective article summarizes CEPI's efforts and strategic considerations for developing a CHIKV vaccine and ensuring equitable access for CHIKV endemic countries.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.